Improvement of Lower Facial Shape after Treatment with OnabotulinumtoxinA: Secondary Results from a Phase 2 Dose Escalation Study.

ABSTRACT:

Background

Masseter muscle prominence (MMP) contributes to a widened lower facial shape, considered aesthetically undesirable to some individuals. This study assessed lower facial shaping improvements with onabotulinumtoxinA.

Methods

In a phase 2, randomized, placebo-controlled study, onabotulinumtoxinA (24, 48, 72, or 96 U) or placebo was injected intramuscularly (3 sites per masseter) into subjects with bilaterally symmetric "marked" or "very marked" MMP on the Masseter Muscle Prominence Scale (MMPS). Changes from baseline at day 90 in lower facial width, mandibular facial angle, investigator-rated MMPS response, subject-perceived symptoms, psychosocial impact of lower face appearance, and satisfaction with lower face on the Lower Facial Shape Questionnaire were assessed.<

SUBMITTER: Liew S 

PROVIDER: S-EPMC12806160 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature